{"id":15887,"date":"2025-02-06T20:36:30","date_gmt":"2025-02-06T20:36:30","guid":{"rendered":"https:\/\/www.gecp.pt\/?p=15887"},"modified":"2025-02-06T20:36:30","modified_gmt":"2025-02-06T20:36:30","slug":"entrevista-dr-a-sonia-silva","status":"publish","type":"post","link":"https:\/\/www.gecp.pt\/en\/entrevista-dr-a-sonia-silva\/","title":{"rendered":"Interview Dr. S\u00f3nia Silva"},"content":{"rendered":"<p>The &#8220;Lecture: Therapeutic targets &#8211; Where we are and where we are going&#8221;, led by Dr. S\u00f3nia Silva, focused on the present and future of therapeutic targets in the treatment of lung cancer. According to the pulmonologist, &#8220;there are currently a series of mutations, and it is essential to identify them as there are targeted therapies emerging at an exponential rate. Some mutations, for which there were no targeted therapies, now present spectacular results for patients&#8221;.<\/p>\n<p>Regarding the challenges, the specialist highlights the issue of toxicity. \u201cTherapies are generally well tolerated, but it is true that they also have their toxicities and particularities and we have to be very aware of them to learn how to deal with them\u201d, explains the pulmonologist. <\/p>\n<p>Another challenge highlighted by Dr. S\u00f3nia Silva relates to combinations of targeted therapies, which in turn lead to more toxicities. Furthermore, these therapies, previously restricted to advanced stages, are now being applied in early stages, introducing new complexities.<\/p><!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>The &#8220;Lecture: Therapeutic targets &#8211; Where we are and where we are going&#8221;, led by Dr. S\u00f3nia Silva, focused on the present and future of therapeutic targets in the treatment of lung cancer. According to the pulmonologist, &#8220;there are currently&#8230;<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>","protected":false},"author":1,"featured_media":15888,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0},"categories":[119,183,118,160],"tags":[],"_links":{"self":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts\/15887"}],"collection":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/comments?post=15887"}],"version-history":[{"count":1,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts\/15887\/revisions"}],"predecessor-version":[{"id":15889,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts\/15887\/revisions\/15889"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/media\/15888"}],"wp:attachment":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/media?parent=15887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/categories?post=15887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/tags?post=15887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}